Last reviewed · How we verify
intrathcal methotrexate
intrathcal methotrexate is a Small molecule drug developed by Hui Bu. It is currently FDA-approved.
Intrathecal methotrexate, marketed by Hui Bu, holds a position in the therapeutic landscape for its indicated use, though specific details on its primary indication and revenue are not provided. A key strength of the drug is its protected market position, with the key composition patent expiring in 2028. The primary risk to consider is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | intrathcal methotrexate |
|---|---|
| Sponsor | Hui Bu |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intrathcal methotrexate CI brief — competitive landscape report
- intrathcal methotrexate updates RSS · CI watch RSS
- Hui Bu portfolio CI
Frequently asked questions about intrathcal methotrexate
What is intrathcal methotrexate?
Who makes intrathcal methotrexate?
What development phase is intrathcal methotrexate in?
Related
- Manufacturer: Hui Bu — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing